Cancer Gene Therapy Market by Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer) - Global Opportunity Analysis and Industry Forecast, 2019 - 2030

Abstract
Market Definition:

The Global Cancer Gene Therapy Market was valued at USD 558.24 million in 2019 and is estimated to reach USD 16.50 billion by 2030, expanding at a CAGR of 32.6% during the forecast period, from 2020 to 2030

Gene therapy is a method of replacing or inactivating the mutated genes responsible for causing diseases or the genes that affect the proper functioning of organs, by introducing a new gene into the body. The adoption of cancer gene therapy is rising due to its high success rate achieved during trials. Cancer gene therapy is used as a substitute of the conventional drugs and surgeries to treat cancer. It has several advantages including high efficacy, minimum side effects and speedy recovery.

Market Dynamics and Trends:

According to the World Health Organization, cancer claimed the lives of nearly 9.6 million in 2018, and is the second-leading cause of death world-wide. At global level, about 1 out of 6 deaths happen due to cancer. Also, improving regulatory standards regarding the quality of products utilized in gene therapy, growing investments for R&D activities, rising popularity of DNA vaccines, ethical acceptance of the gene therapy treatments in treating cancer, are anticipated to fuel the growth of global cancer gene therapy market during the forecast period.

However, cost associated with gene therapy treatment, unwanted immune responses, and risk associated with the treatment are expected to hamper the market growth during the forecast period. On the other hand, growing geriatric population world-wide, favorable reimbursement policies, advancements in product technologies, and untapped market opportunities offered by the emerging economies, are expected to create lucrative opportunities for the market players.

Market Segmentations and Scope of the Study:

The cancer gene therapy market has been segmented based on therapy, end-user, and geography. In terms of therapy, the market has been classified into gene induced immunotherapy, gene transfer, and oncolytic virotherapy. The gene induced immunotherapy segment is further sub-segmented into the delivery of cytokines gene and delivery of tumor antigen gene. The gene transfer segment is sub-segmented into naked/plasmid vectors, sonoportion, magnetofection, electroporation, and gene gun. The oncolytic virotherapy segment is segregated into adenovirus, lentivirus, vaccinia virus, herpes simplex virus, alpha virus, retro virus, adeno associated virus, simian virus, and others. Based on application, the cancer gene therapy market is divided into hospitals, diagnostics centers, and research institutes. On the basis of geography, the market is fragmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW).

Geographical Analysis:

North America dominated the global cancer gene therapy market in 2019, and this trend is expected to continue during the forecast period due to growing geriatric populations, presence of well-established healthcare infrastructure and specialized medical practitioners, advanced technological developments, presence of major manufactures, and high adoption of cancer gene therapy treatment in this region. The market in Asia-Pacific is expected to grow during the forecast period. Increasing consumer awareness about cancer gene therapy owing to increasing government initiatives, improvements in healthcare infrastructures, and untapped market offered in emerging economies.

Competitive Landscape:

Key players in the market are Bluebird bio, Inc., Merck, Adaptimmune, GlaxoSmithKline, Anchiano Therapeutics, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, Celgene, Shanghai Sunway Biotech, and OncoGenex Pharmaceuticals. In January 2020, Merck and AstraZeneca, announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for their regulatory submission of supplemental New Drug Application of LYNPARZA (Olaparib) for the treatment of metastatic castration-resistant prostate cancer and deleterious, suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations, that have progressed a prior treatment with the hormonal agent.

KEY MARKET SEGMENTS:
• Global Cancer Gene Therapy Market – By Therapy
- Gene Induced Immunotherapy
- Delivery of Cytokines Gene
- Delivery of Tumor Antigen Gene
- Gene Transfer
- Naked/Plasmid Vectors
- Sonoportion
- Magnetofection
- Electroporation
- Gene Gun
- Oncolytic Virotherapy
- Adenovirus
- Lentivirus
- Vaccinia Virus
- Herpes Simplex Virus
- Alpha Virus
- Retro Virus
- Adeno Associated Virus
- Simian Virus
- Others
• Global Cancer Gene Therapy Market – By End User
- Hospitals
- Diagnostics Centers
- Research Institutes
• Global Cancer Gene Therapy Market – By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- RoW
- UAE
- Saudi Arabia
- South Africa
- Brazil
- Remaining Countries

KEY PLAYERS:
• Bluebird bio, Inc.
• Merck
• Adaptimmune
• GlaxoSmithKline
• BioCancell
• Shenzhen SiBiono GeneTech
• SynerGene Therapeutics
• Celgene
• Shanghai Sunway Biotech
• OncoGenex Pharmaceuticals

Content
1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. RESEARCH METHODOLOGY
1.2.1 SECONDARY RESEARCH
1.2.2 DATA ANALYSIS FRAMEWORK
1.2.3 MARKET SIZE ESTIMATION
1.2.4 FORECASTING
1.2.5 PRIMARY RESEARCH AND DATA VALIDATION
2. MARKET SNAPSHOT, 2019-2030 MILLION USD
2.1. MARKET SNAPSHOT
3. PORTER’S FIVE FORCE MODEL ANALYSIS
4. MARKET DYNAMICS
4.1. GROWTH DRIVERS
4.1.1 DRIVER 1
4.1.2 DRIVER 2
4.1.3 DRIVER 3
4.1.4 DRIVER 4
4.2. CHALLENGES
4.2.1 CHALLENGE 1
4.2.2 CHALLENGE 2
4.3. OPPORTUNITIES
4.3.1 OPPORTUNITY 1
4.3.2 OPPORTUNITY 2
5. GLOBAL CANCER GENE THERAPY MARKET, BY THERAPY
5.1. OVERVIEW
5.2. GENE INDUCED IMMUNOTHERAPY
5.2.1 GLOBAL GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
5.2.1.1 Adenovirus Market, By Region
5.2.1.1.1 North America Adenovirus Market, By Country
5.2.1.1.2 Europe Adenovirus Market, By Country
5.2.1.1.3 Asia-Pacific Adenovirus Market, By Country
5.2.1.1.4 Rest of World Adenovirus Market, By Country
5.2.1.2 Lentivirus Market, By Region
5.2.1.2.1 North America Lentivirus Market, By Country
5.2.1.2.2 Europe Lentivirus Market, By Country
5.2.1.2.3 Asia-Pacific Lentivirus Market, By Country
5.2.1.2.4 Rest of World Lentivirus Market, By Country
5.2.1.3 Retro Virus Market, By Region
5.2.1.3.1 North America Retro Virus Market, By Country
5.2.1.3.2 Europe Retro Virus Market, By Country
5.2.1.3.3 Asia-Pacific Retro Virus Market, By Country
5.2.1.3.4 Rest of World Retro Virus Market, By Country
5.2.1.4 Adeno Associated Virus Market, By Region
5.2.1.4.1 North America Adeno Associated Virus Market, By Country
5.2.1.4.2 Europe Adeno Associated Virus Market, By Country
5.2.1.4.3 Asia-Pacific Adeno Associated Virus Market, By Country
5.2.1.4.4 Rest of World Adeno Associated Virus Market, By Country
5.2.1.5 Herpes Simplex Virus Market, By Region
5.2.1.5.1 North America Herpes Simplex Virus Market, By Country
5.2.1.5.2 Europe Herpes Simplex Virus Market, By Country
5.2.1.5.3 Asia-Pacific Herpes Simplex Virus Market, By Country
5.2.1.5.4 Rest of World Herpes Simplex Virus Market, By Country
5.2.1.6 Alpha Virus Market, By Region
5.2.1.6.1 North America Alpha Virus Market, By Country
5.2.1.6.2 Europe Alpha Virus Market, By Country
5.2.1.6.3 Asia-Pacific Alpha Virus Market, By Country
5.2.1.6.4 Rest of World Alpha Virus Market, By Country
5.2.1.7 Vaccinia Virus Market, By Region
5.2.1.7.1 North America Vaccinia Virus Market, By Country
5.2.1.7.2 Europe Vaccinia Virus Market, By Country
5.2.1.7.3 Asia-Pacific Vaccinia Virus Market, By Country
5.2.1.7.4 Rest of World Vaccinia Virus Market, By Country
5.2.1.8 Simian Virus Market, By Region
5.2.1.8.1 North America Simian Virus Market, By Country
5.2.1.8.2 Europe Simian Virus Market, By Country
5.2.1.8.3 Asia-Pacific Simian Virus Market, By Country
5.2.1.8.4 Rest of World Simian Virus Market, By Country
5.2.1.9 Others Market, By Region
5.2.1.9.1 North America Others Market, By Country
5.2.1.9.2 Europe Others Market, By Country
5.2.1.9.3 Asia-Pacific Others Market, By Country
5.2.1.9.4 Rest of World Others Market, By Country
5.2.2 GENE INDUCED IMMUNOTHERAPY MARKET, BY REGION
5.2.2.1 North America Gene Induced Immunotherapy Market, By Country
5.2.2.2 Europe Gene Induced Immunotherapy Market, By Country
5.2.2.3 Asia-Pacific Gene Induced Immunotherapy Market, By Country
5.2.2.4 Rest of World Gene Induced Immunotherapy Market, By Country
5.3. ONCOLYTIC VIROTHERAPY
5.3.1 GLOBAL ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
5.3.1.1 Delivery of Cytokines Gene Market, By Region
5.3.1.1.1 North America Delivery of Cytokines Gene Market, By Country
5.3.1.1.2 Europe Delivery of Cytokines Gene Market, By Country
5.3.1.1.3 Asia-Pacific Delivery of Cytokines Gene Market, By Country
5.3.1.1.4 Rest of World Delivery of Cytokines Gene Market, By Country
5.3.1.2 Delivery of Tumor Antigen Gene Market, By Region
5.3.1.2.1 North America Delivery of Tumor Antigen Gene Market, By Country
5.3.1.2.2 Europe Delivery of Tumor Antigen Gene Market, By Country
5.3.1.2.3 Asia-Pacific Delivery of Tumor Antigen Gene Market, By Country
5.3.1.2.4 Rest of World Delivery of Tumor Antigen Gene Market, By Country
5.3.2 ONCOLYTIC VIROTHERAPY MARKET, BY REGION
5.3.2.1 North America Oncolytic Virotherapy Market, By Country
5.3.2.2 Europe Oncolytic Virotherapy Market, By Country
5.3.2.3 Asia-Pacific Oncolytic Virotherapy Market, By Country
5.3.2.4 Rest of World Oncolytic Virotherapy Market, By Country
5.4. GENE TRANSFER
5.4.1 GLOBAL GENE TRANSFER MARKET, BY THERAPY
5.4.1.1 Electroporation Market, By Region
5.4.1.1.1 North America Electroporation Market, By Country
5.4.1.1.2 Europe Electroporation Market, By Country
5.4.1.1.3 Asia-Pacific Electroporation Market, By Country
5.4.1.1.4 Rest of World Electroporation Market, By Country
5.4.1.2 Sonoportion Market, By Region
5.4.1.2.1 North America Sonoportion Market, By Country
5.4.1.2.2 Europe Sonoportion Market, By Country
5.4.1.2.3 Asia-Pacific Sonoportion Market, By Country
5.4.1.2.4 Rest of World Sonoportion Market, By Country
5.4.1.3 Magnetofection Market, By Region
5.4.1.3.1 North America Magnetofection Market, By Country
5.4.1.3.2 Europe Magnetofection Market, By Country
5.4.1.3.3 Asia-Pacific Magnetofection Market, By Country
5.4.1.3.4 Rest of World Magnetofection Market, By Country
5.4.1.4 Gene Gun Market, By Region
5.4.1.4.1 North America Gene Gun Market, By Country
5.4.1.4.2 Europe Gene Gun Market, By Country
5.4.1.4.3 Asia-Pacific Gene Gun Market, By Country
5.4.1.4.4 Rest of World Gene Gun Market, By Country
5.4.2 GENE TRANSFER MARKET, BY REGION
5.4.2.1 North America Gene Transfer Market, By Country
5.4.2.2 Europe Gene Transfer Market, By Country
5.4.2.3 Asia-Pacific Gene Transfer Market, By Country
5.4.2.4 Rest of World Gene Transfer Market, By Country
6. GLOBAL CANCER GENE THERAPY MARKET, BY REGION
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1 NORTH AMERICA CANCER GENE THERAPY MARKET, BY THERAPY
6.2.1.1 North America Gene Induced Immunotherapy Market, By Therapy
6.2.1.2 North America Oncolytic Virotherapy Market, By Therapy
6.2.1.3 North America Gene Transfer Market, By Therapy
6.2.2 NORTH AMERICA CANCER GENE THERAPY, MARKET BY COUNTRY
6.2.2.1 U.S
6.2.2.1.1 U.S Cancer Gene Therapy Market, By Therapy
6.2.2.1.1.1. U.S Gene Induced Immunotherapy Market, By Therapy
6.2.2.1.1.2. U.S Oncolytic Virotherapy Market, By Therapy
6.2.2.1.1.3. U.S Gene Transfer Market, By Therapy
6.2.2.2 Canada
6.2.2.2.1 Canada Cancer Gene Therapy Market, By Therapy
6.2.2.2.1.1. Canada Gene Induced Immunotherapy Market, By Therapy
6.2.2.2.1.2. Canada Oncolytic Virotherapy Market, By Therapy
6.2.2.2.1.3. Canada Gene Transfer Market, By Therapy
6.2.2.3 Mexico
6.2.2.3.1 Mexico Cancer Gene Therapy Market, By Therapy
6.2.2.3.1.1. Mexico Gene Induced Immunotherapy Market, By Therapy
6.2.2.3.1.2. Mexico Oncolytic Virotherapy Market, By Therapy
6.2.2.3.1.3. Mexico Gene Transfer Market, By Therapy
6.3. EUROPE
6.3.1 EUROPE CANCER GENE THERAPY MARKET, BY THERAPY
6.3.1.1 Europe Gene Induced Immunotherapy Market, By Therapy
6.3.1.2 Europe Oncolytic Virotherapy Market, By Therapy
6.3.1.3 Europe Gene Transfer Market, By Therapy
6.3.2 EUROPE CANCER GENE THERAPY, MARKET BY COUNTRY
6.3.2.1 Germany
6.3.2.1.1 Germany Cancer Gene Therapy Market, By Therapy
6.3.2.1.1.1. Germany Gene Induced Immunotherapy Market, By Therapy
6.3.2.1.1.2. Germany Oncolytic Virotherapy Market, By Therapy
6.3.2.1.1.3. Germany Gene Transfer Market, By Therapy
6.3.2.2 France
6.3.2.2.1 France Cancer Gene Therapy Market, By Therapy
6.3.2.2.1.1. France Gene Induced Immunotherapy Market, By Therapy
6.3.2.2.1.2. France Oncolytic Virotherapy Market, By Therapy
6.3.2.2.1.3. France Gene Transfer Market, By Therapy
6.3.2.3 UK
6.3.2.3.1 UK Cancer Gene Therapy Market, By Therapy
6.3.2.3.1.1. UK Gene Induced Immunotherapy Market, By Therapy
6.3.2.3.1.2. UK Oncolytic Virotherapy Market, By Therapy
6.3.2.3.1.3. UK Gene Transfer Market, By Therapy
6.3.2.4 Italy
6.3.2.4.1 Italy Cancer Gene Therapy Market, By Therapy
6.3.2.4.1.1. Italy Gene Induced Immunotherapy Market, By Therapy
6.3.2.4.1.2. Italy Oncolytic Virotherapy Market, By Therapy
6.3.2.4.1.3. Italy Gene Transfer Market, By Therapy
6.3.2.5 Spain
6.3.2.5.1 Spain Cancer Gene Therapy Market, By Therapy
6.3.2.5.1.1. Spain Gene Induced Immunotherapy Market, By Therapy
6.3.2.5.1.2. Spain Oncolytic Virotherapy Market, By Therapy
6.3.2.5.1.3. Spain Gene Transfer Market, By Therapy
6.3.2.6 Rest of Europe
6.3.2.6.1 Rest of Europe Cancer Gene Therapy Market, By Therapy
6.3.2.6.1.1. Rest of Europe Gene Induced Immunotherapy Market, By Therapy
6.3.2.6.1.2. Rest of Europe Oncolytic Virotherapy Market, By Therapy
6.3.2.6.1.3. Rest of Europe Gene Transfer Market, By Therapy
6.4. ASIA-PACIFIC
6.4.1 ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY THERAPY
6.4.1.1 Asia-Pacific Gene Induced Immunotherapy Market, By Therapy
6.4.1.2 Asia-Pacific Oncolytic Virotherapy Market, By Therapy
6.4.1.3 Asia-Pacific Gene Transfer Market, By Therapy
6.4.2 ASIA-PACIFIC CANCER GENE THERAPY, MARKET BY COUNTRY
6.4.2.1 Japan
6.4.2.1.1 Japan Cancer Gene Therapy Market, By Therapy
6.4.2.1.1.1. Japan Gene Induced Immunotherapy Market, By Therapy
6.4.2.1.1.2. Japan Oncolytic Virotherapy Market, By Therapy
6.4.2.1.1.3. Japan Gene Transfer Market, By Therapy
6.4.2.2 China
6.4.2.2.1 China Cancer Gene Therapy Market, By Therapy
6.4.2.2.1.1. China Gene Induced Immunotherapy Market, By Therapy
6.4.2.2.1.2. China Oncolytic Virotherapy Market, By Therapy
6.4.2.2.1.3. China Gene Transfer Market, By Therapy
6.4.2.3 Australia
6.4.2.3.1 Australia Cancer Gene Therapy Market, By Therapy
6.4.2.3.1.1. Australia Gene Induced Immunotherapy Market, By Therapy
6.4.2.3.1.2. Australia Oncolytic Virotherapy Market, By Therapy
6.4.2.3.1.3. Australia Gene Transfer Market, By Therapy
6.4.2.4 India
6.4.2.4.1 India Cancer Gene Therapy Market, By Therapy
6.4.2.4.1.1. India Gene Induced Immunotherapy Market, By Therapy
6.4.2.4.1.2. India Oncolytic Virotherapy Market, By Therapy
6.4.2.4.1.3. India Gene Transfer Market, By Therapy
6.4.2.5 South Korea
6.4.2.5.1 South Korea Cancer Gene Therapy Market, By Therapy
6.4.2.5.1.1. South Korea Gene Induced Immunotherapy Market, By Therapy
6.4.2.5.1.2. South Korea Oncolytic Virotherapy Market, By Therapy
6.4.2.5.1.3. South Korea Gene Transfer Market, By Therapy
6.4.2.6 Taiwan
6.4.2.6.1 Taiwan Cancer Gene Therapy Market, By Therapy
6.4.2.6.1.1. Taiwan Gene Induced Immunotherapy Market, By Therapy
6.4.2.6.1.2. Taiwan Oncolytic Virotherapy Market, By Therapy
6.4.2.6.1.3. Taiwan Gene Transfer Market, By Therapy
6.4.2.7 Rest of Asia-Pacific
6.4.2.7.1 Rest of Asia-Pacific Cancer Gene Therapy Market, By Therapy
6.4.2.7.1.1. Rest of Asia-Pacific Gene Induced Immunotherapy Market, By Therapy
6.4.2.7.1.2. Rest of Asia-Pacific Oncolytic Virotherapy Market, By Therapy
6.4.2.7.1.3. Rest of Asia-Pacific Gene Transfer Market, By Therapy
6.5. REST OF WORLD
6.5.1 REST OF WORLD CANCER GENE THERAPY MARKET, BY THERAPY
6.5.1.1 Rest of World Gene Induced Immunotherapy Market, By Therapy
6.5.1.2 Rest of World Oncolytic Virotherapy Market, By Therapy
6.5.1.3 Rest of World Gene Transfer Market, By Therapy
6.5.2 REST OF WORLD CANCER GENE THERAPY, MARKET BY COUNTRY
6.5.2.1 Brazil
6.5.2.1.1 Brazil Cancer Gene Therapy Market, By Therapy
6.5.2.1.1.1. Brazil Gene Induced Immunotherapy Market, By Therapy
6.5.2.1.1.2. Brazil Oncolytic Virotherapy Market, By Therapy
6.5.2.1.1.3. Brazil Gene Transfer Market, By Therapy
6.5.2.2 Turkey
6.5.2.2.1 Turkey Cancer Gene Therapy Market, By Therapy
6.5.2.2.1.1. Turkey Gene Induced Immunotherapy Market, By Therapy
6.5.2.2.1.2. Turkey Oncolytic Virotherapy Market, By Therapy
6.5.2.2.1.3. Turkey Gene Transfer Market, By Therapy
6.5.2.3 Saudi Arabia
6.5.2.3.1 Saudi Arabia Cancer Gene Therapy Market, By Therapy
6.5.2.3.1.1. Saudi Arabia Gene Induced Immunotherapy Market, By Therapy
6.5.2.3.1.2. Saudi Arabia Oncolytic Virotherapy Market, By Therapy
6.5.2.3.1.3. Saudi Arabia Gene Transfer Market, By Therapy
6.5.2.4 South Africa
6.5.2.4.1 South Africa Cancer Gene Therapy Market, By Therapy
6.5.2.4.1.1. South Africa Gene Induced Immunotherapy Market, By Therapy
6.5.2.4.1.2. South Africa Oncolytic Virotherapy Market, By Therapy
6.5.2.4.1.3. South Africa Gene Transfer Market, By Therapy
6.5.2.5 Remaining Countries
6.5.2.5.1 Remaining Countries Cancer Gene Therapy Market, By Therapy
6.5.2.5.1.1. Remaining Countries Gene Induced Immunotherapy Market, By Therapy
6.5.2.5.1.2. Remaining Countries Oncolytic Virotherapy Market, By Therapy
6.5.2.5.1.3. Remaining Countries Gene Transfer Market, By Therapy
7. COMPANY PROFILES
7.1. ADAPTIMMUNE
7.1.1 COMPANY OVERVIEW
7.1.2 COMPANY SNAPSHOT
7.1.3 OPERATING BUSINESS SEGMENTS
7.1.4 PRODUCT PORTFOLIO
7.1.5 BUSINESS PERFORMANCE
7.1.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.2. GLAXOSMITHKLINE
7.2.1 COMPANY OVERVIEW
7.2.2 COMPANY SNAPSHOT
7.2.3 OPERATING BUSINESS SEGMENTS
7.2.4 PRODUCT PORTFOLIO
7.2.5 BUSINESS PERFORMANCE
7.2.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.3. BLUEBIRD BIO, INC.
7.3.1 COMPANY OVERVIEW
7.3.2 COMPANY SNAPSHOT
7.3.3 OPERATING BUSINESS SEGMENTS
7.3.4 PRODUCT PORTFOLIO
7.3.5 BUSINESS PERFORMANCE
7.3.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.4. MERCK
7.4.1 COMPANY OVERVIEW
7.4.2 COMPANY SNAPSHOT
7.4.3 OPERATING BUSINESS SEGMENTS
7.4.4 PRODUCT PORTFOLIO
7.4.5 BUSINESS PERFORMANCE
7.4.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.5. CELGENE
7.5.1 COMPANY OVERVIEW
7.5.2 COMPANY SNAPSHOT
7.5.3 OPERATING BUSINESS SEGMENTS
7.5.4 PRODUCT PORTFOLIO
7.5.5 BUSINESS PERFORMANCE
7.5.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.6. SHANGHAI SUNWAY BIOTECH
7.6.1 COMPANY OVERVIEW
7.6.2 COMPANY SNAPSHOT
7.6.3 OPERATING BUSINESS SEGMENTS
7.6.4 PRODUCT PORTFOLIO
7.6.5 BUSINESS PERFORMANCE
7.6.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.7. BIOCANCELL
7.7.1 COMPANY OVERVIEW
7.7.2 COMPANY SNAPSHOT
7.7.3 OPERATING BUSINESS SEGMENTS
7.7.4 PRODUCT PORTFOLIO
7.7.5 BUSINESS PERFORMANCE
7.7.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.8. SHENZHEN SIBIONO GENETECH
7.8.1 COMPANY OVERVIEW
7.8.2 COMPANY SNAPSHOT
7.8.3 OPERATING BUSINESS SEGMENTS
7.8.4 PRODUCT PORTFOLIO
7.8.5 BUSINESS PERFORMANCE
7.8.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.9. SYNERGENE THERAPEUTICS
7.9.1 COMPANY OVERVIEW
7.9.2 COMPANY SNAPSHOT
7.9.3 OPERATING BUSINESS SEGMENTS
7.9.4 PRODUCT PORTFOLIO
7.9.5 BUSINESS PERFORMANCE
7.9.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.10. ONCOGENEX PHARMACEUTICALS
7.10.1 COMPANY OVERVIEW
7.10.2 COMPANY SNAPSHOT
7.10.3 OPERATING BUSINESS SEGMENTS
7.10.4 PRODUCT PORTFOLIO
7.10.5 BUSINESS PERFORMANCE
7.10.6 KEY STRATEGIC MOVES AND DEVELOPMENT